These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 10570037

  • 1. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
    Fiorani P, Amatruda JF, Silvestri A, Butler RH, Bjornsti MA, Benedetti P.
    Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
    [Abstract] [Full Text] [Related]

  • 2. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
    van der Merwe M, Bjornsti MA.
    J Biol Chem; 2008 Feb 08; 283(6):3305-3315. PubMed ID: 18056711
    [Abstract] [Full Text] [Related]

  • 3. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.
    Woo MH, Vance JR, Marcos AR, Bailly C, Bjornsti MA.
    J Biol Chem; 2002 Feb 08; 277(6):3813-22. PubMed ID: 11733535
    [Abstract] [Full Text] [Related]

  • 4. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.
    Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti MA, Benedetti P.
    J Biol Chem; 2007 Mar 30; 282(13):9855-9864. PubMed ID: 17276985
    [Abstract] [Full Text] [Related]

  • 5. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance.
    Losasso C, Cretaio E, Fiorani P, D'Annessa I, Chillemi G, Benedetti P.
    Nucleic Acids Res; 2008 Oct 30; 36(17):5635-44. PubMed ID: 18772225
    [Abstract] [Full Text] [Related]

  • 6. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
    Wright CM, van der Merwe M, DeBrot AH, Bjornsti MA.
    J Biol Chem; 2015 May 08; 290(19):12068-78. PubMed ID: 25795777
    [Abstract] [Full Text] [Related]

  • 7. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate.
    Fertala J, Vance JR, Pourquier P, Pommier Y, Bjornsti MA.
    J Biol Chem; 2000 May 19; 275(20):15246-53. PubMed ID: 10809761
    [Abstract] [Full Text] [Related]

  • 8. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.
    Fiorani P, Bruselles A, Falconi M, Chillemi G, Desideri A, Benedetti P.
    J Biol Chem; 2003 Oct 31; 278(44):43268-75. PubMed ID: 12904303
    [Abstract] [Full Text] [Related]

  • 9. Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.
    Colley WC, van der Merwe M, Vance JR, Burgin AB, Bjornsti MA.
    J Biol Chem; 2004 Dec 24; 279(52):54069-78. PubMed ID: 15489506
    [Abstract] [Full Text] [Related]

  • 10. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y, Weinstein JN, Kohn KW, Shi LM, Pommier Y.
    J Med Chem; 1998 Jun 18; 41(13):2216-26. PubMed ID: 9632354
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, Pommier Y.
    Cancer Res; 2001 Mar 01; 61(5):1964-9. PubMed ID: 11280753
    [Abstract] [Full Text] [Related]

  • 15. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
    Benedetti P, Fiorani P, Capuani L, Wang JC.
    Cancer Res; 1993 Sep 15; 53(18):4343-8. PubMed ID: 8395982
    [Abstract] [Full Text] [Related]

  • 16. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
    D'Annessa I, Tesauro C, Wang Z, Arnò B, Zuccaro L, Fiorani P, Desideri A.
    Biochim Biophys Acta; 2013 Dec 15; 1834(12):2712-21. PubMed ID: 24096022
    [Abstract] [Full Text] [Related]

  • 17. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.
    Woo MH, Losasso C, Guo H, Pattarello L, Benedetti P, Bjornsti MA.
    Proc Natl Acad Sci U S A; 2003 Nov 25; 100(24):13767-72. PubMed ID: 14585933
    [Abstract] [Full Text] [Related]

  • 18. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons.
    Knab AM, Fertala J, Bjornsti MA.
    J Biol Chem; 1995 Mar 17; 270(11):6141-8. PubMed ID: 7890748
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
    Alessandri M, Beretta GL, Ferretti E, Mancia A, Khobta A, Capranico G.
    J Mol Biol; 2004 Mar 19; 337(2):295-305. PubMed ID: 15003448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.